Objectives: Restoring a functional beta-cell mass is a fundamental goal in treating diabetes. A complex signalling pathway network coordinates the regulation of beta-cell proliferation, although a role for ERK5 in this network has not been reported. This question was addressed in this study.
| INTRODUCTION
Diabetes, often referred to as diabetes mellitus, describes a group of prevalent metabolic diseases in which the patient has high blood sugar, due to inadequate insulin production by pancreatic beta cells or improper body responses to insulin. 1 There are two types of diabetes, type 1 diabetes and type 2 diabetes, which are different in disease prevalence and pathogenesis; however, both share a gradual loss-offunctional beta-cell mass. 1 Indeed, past studies have demonstrated that restoring functional beta-cell mass is a fundamental goal in treating diabetic patients. 1 We and others have shown that increases in adult beta-cell number preliminarily stem from beta-cell self-replication. [2] [3] [4] [5] [6] An established opinion upon the control of beta-cell proliferation highlights the coordinating role of a complex signalling pathway network. [7] [8] [9] [10] [11] [12] [13] Among the many molecules that participate in this sophisticated regulation, the mitogen-activated protein kinases (MAPKs) and their downstream targets appear to be essential signalling modules. There are four major subfamilies of MAPKs: the extracellular-signal-regulated kinases (ERK1/2), the p38 kinases, the Jun amino-terminal kinases (JNKs) and extracellular-signal-regulated kinase 5 (ERK5). ERK1/2 are the most frequently studied MAPK in pancreatic beta cells, and platelet-derived growth factor (PDGF) 14 and insulin-like growth factor 1 (IGF-1) [15] [16] [17] have independently been shown to activate Ras/c-Raf/ERK1/2 to promote beta-cell proliferation. Moreover, JNKs were found to be mainly involved in regulating beta-cell stress and apoptosis, [18] [19] [20] [21] [22] [23] while p38 kinases appeared to be involved in control of both beta-cell proliferation and apoptosis. [24] [25] [26] [27] [28] However, a role of ERK5 in the control of beta-cell proliferation or beta-cell apoptosis has not been examined. 30 In another study, elevated blood glucose and compromised insulin sensitivity were detected in adipocytespecific ERK5-deficient mice. 31 In addition, ERK5 was found to protect against pancreatic beta-cell apoptosis and hyperglycaemia in mice by interrupting the ER stress-mediated apoptotic pathway. 32 Since cellular apoptosis and proliferation often share regulatory components, 33 we hypothesized that ERK5 may play a role in beta-cell proliferation in certain settings and thus studied it in pregnant mice, a well-accepted model for beta-cell proliferation.
34-38
Here, we found that ERK5 phosphorylation, which represents ERK5 activation, was significantly upregulated in islets from pregnant mice. Suppression of ERK5 activation by a specific inhibitor of ERK5 activation, BIX02189, in pregnant mice significantly reduced betacell proliferation, without affecting beta-cell apoptosis, resulting in increases in random blood glucose levels and impairment of glucose responses of the mice. Moreover, ERK5 seemed to activate CyclinD1 to promote gestational beta-cell proliferation. These data suggest that ERK5 may play an essential role in the gestational augmentation of beta-cell proliferation and could be a target for increasing beta-cell mass in diabetes patients.
| MATERIALS AND METHODS

| Protocol and mouse treatment
All animal experiments were approved by the Animal Research and Care Committee at Wenzhou Medical University. C57BL/6 mice were purchased from the SLAC Laboratory Animal Co. Ltd (Shanghai, China). Pregnancy was induced in female mice at 12 weeks of age by a timed breeding, and the pregnant mice were analysed at gestational day 15. The ERK5 inhibitor BIX02189 (Selleck Chemicals, Houston, TX, USA) was intraperitoneally injected into the pregnant mice from gestational day 1 to day 15 (time of analysis) at a dose of 10 mg/kg body weight in 100 mL saline once per day. The control mice received the same volume of saline and at the same frequency.
| Random blood glucose and glucose tolerance test
Random blood glucose and glucose tolerance were measured as has been previously described. 6, 11, 13, 39 Briefly, the mice were not fasted and blood samples were obtained at around 10 am by tail tip puncture using a glucometer (Accu-Chek, Roche, Nutley, NJ, USA). To determine the glucose tolerance, after a 16-hour fasting, the mice received an intraperitoneal injection of dextrose (2 mg/g body weight)
and blood samples were obtained by tail clipping at 0, 15, 30, 60 and 120 minutes.
| Ki-67 staining, TUNEL staining, quantification of proliferating/apoptotic beta cells and beta-cell mass
Tissues were fixed in 4% paraformaldehyde at 4°C for 6 hours, followed by cryoprotection in 30% sucrose for 16 hours before snapfreezing. Sectioning was performed to prepare slides of 6 μm thickness. All slides were incubated with primary antibodies at 4°C
overnight, then incubated with secondary antibodies for 2 hours at room temperature. Primary antibodies used in this study were Guinea 
| Pancreatic digestion and islet isolation
Mouse pancreas digestion and islet isolation were performed as described before. [42] [43] [44] [45] Briefly, the pancreas was infused with 0.25 mg/ mL collagenase P (Sigma-Aldrich, St. Louis, MO, USA) for 40 minutes to obtain a single-cell population. Islets were handpicked at least five times to avoid contamination of non-islets.
| Western blotting
Western blotting was performed as previously described. 11, 39, 40 Primary antibodies for Western blot are rabbit anti-GAPDH (Cell Signaling, San Jose, CA, USA), rabbit anti-ERK5 (Cell Signaling), rabbit anti-pERK5 (Cell Signaling) and rabbit anti-CyclinD1 (Santa Cruz Biotechnology, Dallas, TX, USA). Secondary antibody is HRPconjugated anti-rabbit antibody (Dako).
| Data Analysis
GraphPad Prism 6.0 (GraphPad Software, Inc., La Jolla, CA, USA) was used for statistical analyses. All values are depicted as mean ± SD.
Five repeats were analysed in each condition. All data were statistically analysed using one-way ANOVA with a Bonferroni correction, followed by Fisher's exact test to compare two groups. Significance was considered when P < .05.
| RESULTS
| Significantly increased beta-cell proliferation and elevated beta-cell mass are detected in pregnant mice at gestational day 15
During pregnancy, beta-cell proliferation significantly increases in response to augmented metabolic need. [34] [35] [36] [37] [38] Based on previous findings from us 6 and from others, 46 the peak of beta-cell proliferation appears to be from gestational day 13 to 16. Thus, in this study, we focused on gestational day 15. We found that at gestational day 15, beta-cell mass was significantly increased, compared with control non-pregnant littermates ( Figure 1A ). This significant increase in beta-cell mass appeared to stem from the significant increases in beta-cell proliferation, shown by quantification of Ki67 + beta cells ( Figure 1B ) and representative Ki-67 staining images ( Figure 1C ), rather than from an alteration in beta-cell apoptosis, shown by quantification of TUNEL + beta cells ( Figure 1D ) and representative TUNEL staining images ( Figure 1E ).
| ERK5 is activated in beta cells from pregnant mice
Mouse islets were, thus, isolated from pregnant mice at gestational day 15, and compared with those from non-pregnant littermates (Figure 2A ). We found that the total ERK5 in islets from pregnant mice remained unaltered ( Figure 2B, C) , while the phosphorylated ERK5 was significantly increased in islets from pregnant mice, compared with those from non-pregnant littermates ( Figure 2B,D) .
Thus, ERK5 activation in beta cells occurs concomitantly with pregnancy.
| Activation of ERK5 in beta cells is suppressed by BIX02189 in pregnant mice
In order to figure out whether the activation of ERK5 in beta cells may be necessary for the augmentation of beta-cell proliferation during pregnancy, we injected a specific inhibitor of ERK5 activation, BIX02189, into the pregnant mice to suppress ERK5 signalling. At gestational day 15, mouse islets were isolated and examined for the levels of ERK5 and pERK5. We found that the total ERK5 in islets from the pregnant mice that had received either BIX02189 or control saline did not alter ( Figure 3A, B) , while the phosphorylated ERK5 was significantly decreased in islets from the pregnant mice that had received BIX02189, compared with those from the pregnant mice that had received saline ( Figure 3A,C) . Thus, activation of ERK5 in beta cells in pregnant mice is suppressed by BIX02189 injections.
| Suppression of ERK5 activation impairs gestational beta-cell proliferation
We found that at gestational day 15, the random blood glucose in pregnant mice that had received BIX02189 was significantly higher, compared with the measurements from pregnant mice that had received saline ( Figure 4A ). Moreover, the glucose tolerance in the mice that had received BIX02189 was also significantly poorer, compared with pregnant mice that had received saline or control non-pregnant mice ( Figure 4B ). Next, beta-cell proliferation, beta-cell apoptosis and beta-cell mass were quantified. We found that at gestational day 15, increases in beta-cell mass in mice that had received BIX02189 were significantly compromised, compared with the pregnant mice that had received saline ( Figure 4C ). The attenuated increases in beta-cell mass by BIX02189 injections appeared to stem from the significant attenuation in beta-cell proliferation, shown by quantification of Ki67 + beta cells ( Figure 4D ) and representative Ki-67 staining images ( Figure 4E ), rather than from an alteration in beta-cell apoptosis, shown by quantification of TUNEL + beta cells ( Figure 4F ) and representative TUNEL staining images ( Figure 4G ). Together, these data suggest that suppression of ERK5 activation impairs gestational beta-cell proliferation and increases in beta-cell mass.
| ERK5 seems to activate CyclinD1 to promote gestational beta-cell proliferation
Finally, we investigated the downstream signalling molecules for ERK5-mediated upregulation of beta-cell proliferation. A previous study has shown that ERK5 activation promotes cell proliferation through CyclinD1, a key cell-cycle activator that promotes G1/s phase transition, in a fibroblast cell line. 47 Thus, we examined the levels of CyclinD1 in beta cells from non-pregnant mice, pregnant mice that had received BIX02189 and pregnant mice that had received saline. We found that CyclinD1 levels were significantly increased in beta cells from pregnant mice, compared with non-pregnant mice, but this increase in CyclinD1 levels was abolished by BIX02189 injections ( Figure 5A ). Hence, ERK5 seems to promote gestational betacell proliferation at least partially through upregulating CyclinD1
( Figure 5B ).
| DISCUSSION
Accumulating evidence in the past years shows that adult beta-cell proliferation is controlled by a number of signalling pathways that share certain molecular cascades. 10 For example, we have investigated the role of transforming growth factor receptor (TGF-beta) signalling and epidermal growth factor (EGF) receptor signalling in beta-cell proliferation and proposed that beta-cell proliferation can be activated either actively in response to a metabolic need/beta-cell workload or passively in response to inflammatory stimulants. [11] [12] [13] 42 Interestingly, although these 2 ways to induce beta-cell proliferation may mainly use different signalling pathways, some part of the pathway may share F I G U R E 2 Extracellular-signalregulated kinase 5 (ERK5) is activated in beta cells from pregnant mice. A, Images of purified mouse islets isolated from control non-pregnant littermates (NOP) or from pregnant mice at gestational day 15 (PRG). B, Representative Western blotting for pERK5, ERK5 and GAPDH. C, Quantification of ERK5 levels (normalized to GAPDH). D, Quantification of pERK5 levels (normalized to ERK5). *P < .05. NS, no significance, n = 5.
F I G U R E 3 Activation of extracellular-signal-regulated kinase 5 (ERK5) in beta cells is suppressed by BIX02189 in pregnant mice. A specific inhibitor of ERK5 activation, BIX02189 (BIX), was injected into the pregnant mice once per day from gestational day 1 to day 15 to suppress ERK5 signalling. The control pregnant mice received the same volume of saline and at the same frequency (saline). At gestational day 15, mouse islets were isolated and examined for levels of ERK5 and pERK5. A, Representative Western blotting for pERK5, ERK5 and GAPDH. B, Quantification of ERK5 levels (normalized to GAPDH). C, Quantification of pERK5 levels (normalized to ERK5). *P < .05. NS, no significance, n = 5. Among all signalling molecules, MAPKs are factors that are connected to different pathways. As a focus of this study, ERK5 can be activated through NGF and its receptor TrkA at the nerve terminal, 48 or be activated through G-CSF/G-CSF receptor in the regulation of granulopoiesis, 49 or be activated through TGF-beta/TGF-beta receptor in the control of function and survival of podocytes. 50 However, the association of ERK5 with Hsp90 and Cdc37 super-chaperone renders ERK5 a regulator of other signalling pathways that include Hsp90 or Cdc37 as involved molecules. 29 For example, Hsp90 is a chaperone required for the conformation of several signalling proteins including Raf, cdk4 and steroid receptors. 51 Hsp90 can stabilize TGF-beta receptors and prevent ubiquitin-mediated degradation of TGF-beta receptors.
52,53
Moreover, like ERK5, intracellular Akt is also associated with Hsp90 and Cdc37 in a complex that is regulated by phosphatidylinositol 3-kinase.
54
Thus, ERK5 appears to be an important molecule that may affect many signalling pathways controlling beta-cell proliferation and apoptosis.
Here, we investigated the changes in ERK5 activation in primary mouse islets during pregnancy. To the best of our knowledge, CyclinD1 was identified as a target for ERK5 in beta cells, similar to a fibroblast cell line in a previous report. 47 In our past studies, we have shown that CyclinD1 is an important molecule involved in both SMAD7-mediated 11 and EGFR signalling-activated beta-cell proliferation. 12 Future studies may apply proper pathway inhibitors in knockout animals to further investigate the interaction among pathways that may be affected by ERK5, in order to increase our knowledge on the coordination of beta-cell proliferation. This study suggests that ERK5 may be a promising target for increasing beta-cell mass in diabetes patients.
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F I G U R E 4 Suppression of extracellular-signal-regulated kinase 5 (ERK5) activation impairs gestational beta-cell proliferation. At gestational day 15, the mice were analysed. A, The random blood glucose in pregnant mice that had received BIX02189 (BIX) and in the pregnant mice that had received saline (saline) was determined. B, The glucose tolerance in BIX and saline-treated from pregnant mice at gestational day 15 (PRG) and control non-pregnant littermates (NOP) was determined by IPGTT. C, Beta-cell mass. D-E, Beta-cell proliferation was determined by Ki-67 + beta cells, shown by quantification of Ki67 + INS + cells (D) and representative images (E). A square inset in white was shown for each panel in E.
F-G, Beta-cell apoptosis was determined by terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labelling (TUNEL) + beta cells, shown by quantification of TUNEL + INS + cells (F) and representative images (G). *P < .05. NS, no significance, n = 5. Scale bars are 50 μm.
F I G U R E 5 Extracellular-signalregulated kinase 5 (ERK5) seems to activate CyclinD1 to promote gestational beta-cell proliferation. A, The levels of CyclinD1 in beta cells from non-pregnant mice (NOP), pregnant mice that had received BIX02189 (BIX) and pregnant mice that had received saline (saline) were determined by Western blotting. B, Schematic of the model: ERK5 seems to promote gestational betacell proliferation through upregulating CyclinD1. *P < .05; n = 5.
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